Brokerages Set BioNTech SE (NASDAQ:BNTX) Target Price at $120.40

BioNTech SE (NASDAQ:BNTX) has earned an average rating of “Hold” from the ten brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $120.40.

Several brokerages have recently issued reports on BNTX. The Goldman Sachs Group decreased their price target on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 28th. HC Wainwright reissued a “buy” rating and issued a $107.00 price target on shares of BioNTech in a report on Wednesday. JPMorgan Chase & Co. decreased their price target on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a report on Friday, March 22nd. Canaccord Genuity Group reissued a “buy” rating and issued a $171.00 price target on shares of BioNTech in a report on Thursday, March 21st. Finally, UBS Group decreased their price target on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a report on Wednesday, March 27th.

Hedge Funds Weigh In On BioNTech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BNTX. GAMMA Investing LLC boosted its stake in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the period. CWM LLC boosted its stake in BioNTech by 657.6% in the 4th quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after purchasing an additional 217 shares during the period. State of Wyoming bought a new stake in BioNTech during the 2nd quarter worth about $26,000. Frazier Financial Advisors LLC bought a new stake in BioNTech during the 4th quarter worth about $30,000. Finally, Covestor Ltd bought a new stake in BioNTech during the 3rd quarter worth about $32,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Price Performance

BNTX opened at $86.17 on Tuesday. The company has a fifty day moving average price of $91.33 and a two-hundred day moving average price of $97.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. BioNTech has a 52 week low of $85.21 and a 52 week high of $125.83. The firm has a market capitalization of $20.49 billion, a PE ratio of 20.92 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last released its earnings results on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. As a group, analysts anticipate that BioNTech will post -1.67 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.